Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

FACULTY

Matthew A. Lunning, DO
Assistant Professor
Department of Internal Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska, USA

Alison G. Freifeld, MD
Professor of Internal Medicine
Director, Immunocompromised Host Infectious Diseases Program
Department of Internal Medicine
Division of Infectious Diseases
Fred & Pamela Buffett Cancer Center at Nebraska Medicine
Omaha, Nebraska, USA

James S. Lewis, II, PharmD, FIDSA
ID Clinical Pharmacy Coordinator
Oregon Health and Science University
Portland, Oregon, USA

Johan Maertens, MD, PhD
University Hospital Gasthuisberg Leuven
Department of Hematology
Leuven, Belgium

Eric J. Bow MD, MSc, DBacteriol, FRCPC
Professor, Departments of Medical Microbiology and Infectious Diseases, and Internal Medicine
Sections of Infectious Diseases and Hematology/Oncology
The University of Manitoba
Director, Infection Control Services
CancerCare Manitoba
Winnipeg, Manitoba, Canada

FINANCIAL DISCLOSURE

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

MATTHEW A. LUNNING, DO
ADVISOR/CONSULTANT:
Alexion; Celgene; Genentech, Inc; Gilead Sciences, Inc.; Juno; Spectrum Pharmaceuticals, Inc.; TG Therapeutics

ERIC J. BOW, MD, MSc, D. Bacteriol, FRCPC
CONSULTANT:
Gilead Sciences; Gly-Pharma; Pfizer
REVIEW PANEL MEMBER:
Astellas
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
Discussion of investigational agents and diagnostics for IFIs

ALISON G. FREIFELD, MD
DATA SAFETY MONITORING BOARD:
Astellas Pharma Global Development; Merck & Co., Inc.

JAMES S. LEWIS, II, PharmD, FIDSA
CONSULTANT:
Accelerate Diagnostics; Astellas; Cubist; Merck & Co., Inc.; Theravance Inc.

JOHAN  MAERTENS, MD, PhD
GRANT RECIPIENT/ADVISOR/SPEAKERS BUREAU MEMBER:
Astellas; Bio-Rad; Gilead Sciences; Merck, Sharp and Dohme; Pfizer Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Lisa A. Tushla, PhD, H(ASCP), of Terranova Medica, LLC, reports no financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

ACCREDITATION STATEMENT

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: 0809-9999-16-275-H01-P
Credits: 2.0 hours (0.20 ceu)

Published: April 30, 2016
Expires:  April 29, 2017

Type of Activity: Knowledge

Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes

TARGET AUDIENCE

This accredited activity has been designed for pharmacists.

HOW TO EARN CREDIT

During the period April 30, 2016 through April 29, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

The goal of this activity is to support clinical pharmacists in their efforts to serve as expert members of the interdisciplinary care team in preventing and managing invasive fungal disease and improving outcomes for patients with hematologic malignancies.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

• Define the current and evolving burden of IFIs
• Compare available and emerging diagnostics and therapies for management of IFIs
• Apply optimal strategies for prophylactic, empiric, pre-emptive, and definitive treatment of IFIs in hematologic malignancy patients
• Engage the multidisciplinary care team in the optimal management of IFIs in challenging hematologic malignancy cases
• Provide accurate and appropriate counsel as part of the treatment team

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

DISCLOSURE OF UNLABELED USE AND DISCLAIMER

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.